[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1469 Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I
Saturday, December 7, 2013, 5:30 PM-7:30 PM
Hall E (Ernest N. Morial Convention Center)

Robert Erdmann, PhD MSc1,2*, Heather Jorgensen, PhD3*, Alexander Schultze, MD, MSc1,2*, Gunhild von Amsberg, MD2*, Isabel Ben-Battala, PhD, MSc1,2*, Mark Wroblewski, MSc1,2*, Miguel Cubas Cordova, MSc1,2*, Stefanie Sawall1,2*, Victoria Witzke1,2*, Elaine K Allan4*, Leena Mukherjee, PhD5*, Heather Morrison5*, Jennifer Cassels5*, Philippe Schafhausen, MD2*, Nicolaus Kroeger, MD6, James Lorens, MD7*, Richard E. Clark, MBBS, MD, FRCP, FRCPath8, Peter Vandenberghe, MD, PhD9*, Tim H. Brümmendorf, MD10, Andreas Hochhaus, MD11, Peter Carmeliet, MD, PhD12*, Klaus Pantel, MD, PhD1*, Carsten Bokemeyer, MD2,13*, Tessa L. Holyoake, PhD, FRCP, FRCPath5 and Sonja Loges, MD, PhD1,2*

1Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2II. Medical Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
3Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
4Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom
5Paul O`Gorman Leukemia Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
6Center of Oncology - Bone Marrow Transplantation Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7Department of Biomedicine, University of Bergen, Bergen, Norway
8Royal Liverpool University Hospital, University of Liverpool, Liverpool, United Kingdom
9Center for Human Genetics, Katholieke Universiteit - Leuven, Leuven, Belgium
10Universitätsklinikum RWTH Aachen, Aachen, Germany
11Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
12VIB - Katholieke Universiteit Leuven, Vesalius Research Center, Leuven, Belgium
13Hematology/Oncology/Tumor Immunology, University Hospital Hamburg Eppendorf, Hamburg, Germany

BCR-ABL1 inhibitors have revolutionized treatment of CML patients. However several drawbacks remain, including therapy resistance of T315I-mutated CML and incapability of current drugs to eliminate quiescent CML stem cells warranting development of novel therapies. In addition, drugs with the potential to enhance efficacy of BCR-ABL1 targeting agents could improve treatment of CML patients. Members of the Tyro3, Axl, Mer receptor (TAMR) tyrosine kinase family are abundantly expressed in physiological and malignant hematopoiesis and their ligand Gas6 can support hematopoietic (progenitor) cells. Evidence in the literature indicates that Axl is upregulated upon treatment with imatinib (IM).

In this study, we investigated the relevance of the Gas6-Axl axis in CML patients and the therapeutic potential of the clinically applicable small molecule Axl inhibitor BGB324 (former designation R428) in primary CML (stem cell) samples, cell lines and preclinical models.

In a first step we quantified Axl-expressing cells by flow cytometry in chronic phase (CP) CML bone marrow at primary diagnosis and healthy bone marrow donors. Here, we found higher numbers of Axl-positive cells in CML bone marrow compared to controls (11.42±0.42% (n=5) vs. 0.65±0.10% (n=6), respectively; p=0.0015). In addition, we determined Gas6 plasma levels by ELISA in healthy controls and CML patients in CP and blast crisis (BC). These analyses revealed that Gas6 plasma levels were upregulated in a stage specific manner (plasma levels of Gas6: healthy controls 1290±684 pg/ml (n=14), CP 3465±405 pg/ml (n=50), BC 10940±3868 pg/ml (n=7); p=0.0001). Thus, the Gas6-Axl axis represents a potential therapeutic target in CML patients.

Based on this finding we analyzed efficacy of BGB324 in Axl-expressing  BV173, KCL22, K562, BaF3_BCR-ABL1-wt and BaF3_BCR-ABL1-T315I cell lines in vitro. We found inhibition of proliferation in all analyzed cell lines with IC50 values ranging from 500-3000 nM. Combination experiments with the IC50 dose of BGB324 and IM revealed additive effects of both treatments in all cell lines. Dose finding experiments with BGB324 in sorted CD34+ primary CML cells grown in the presence of physiological growth factors yielded a mean IC50 of 1.1 ± 0.3 mM (n=3), which was similar to nilotinib. BGB324 did not accumulate CD34+CFSEmax (undivided) cells any more than nilotinib but enhanced apoptosis of CD34+ cells in combination with nilotinib. Notably, there was a consistent inhibitory effect of 3 mM BGB324 alone or in combination with nilotinib against colony forming cells (CFC) with the more primitive BFU-E and GEMM being most sensitive to inhibition (n=4). Interestingly, the Ph- lymphocytes (confirmed by FISH) sorted simultaneously with Ph+ CD34+ cells from the same CML patient were unaffected in terms of viability when treated with Axl inhibitor; thus the BGB324’s activity is cell context specific.

Encouraged by these data we analyzed efficacy of BGB324 in an aggressive preclinical CML model in which bone marrow cells were retrovirally transduced with constructs containing T315I-mutated BCR-ABL1. Transduced cells were subsequently i.v. transplanted into sublethally irradiated recipient mice, who rapidly developed blast crisis CML. Mice were treated with 25 mg BGB324 or vehicle BID by oral gavage starting from day 3 after transplantation when homing of transduced cells to the bone marrow is completed. In this model we found a significant prolongation of survival upon treatment with BGB324 (Figure 1). Analyses of the leukemia phenotype by differential blood counts and flow cytometry revealed that BGB324 reduced leukemia cell burden (WBC 138±20x103/µl (n=14) vs. 60x103±21 k/µl WBC in the BGB324 treated group (n=13); p=0.0078).

Taken together, these data suggest that the Gas6-Axl axis represents a therapeutic target and that BGB324 is a potent molecule effective against T315I-mutated and wt CML alone and in combination with TKI. Furthermore, BGB324 induces apoptosis of quiescent Ph+ CML stem/progenitor cells. Thus

BGB324 might open up novel therapeutic avenues in CML patients.

 

<![if !vml]><![endif]>

Disclosures: Loges: BerGenBio: research support Other.

*signifies non-member of ASH